Preliminary clinical assessment and non- toxicity evaluation of an ayurvedic formulation BGR-34 in NIDDM

10.1016/j.jtcme.2017.11.004

B.P. Gupta；I. Sharma；N. Kohli；S. Sharma；A. Rathi；A.K. Sharma

BGR-34 ； Berberis aristata ； NIDDM ； Indian system medicine ； Type 2 diabetes

Journal of Traditional and Complementary Medicine

8卷4期（2018 / 10 / 01）

506 - 514

英文

In view of the overall health impact of NIDDM, inventers understand the necessity of improving glycemic control in adults with type 2 diabetes. BGR-34 provides an effective treatment option for adults with type 2 diabetes who have been inadequately controlled on lifestyle with or without other oral hypoglycemic agents (OHGAs) such as metformin, sulfonylurea, or a glitazones. BGR-34 is an appropriate option to consider for addition to a managed care drug formulary. Treatment with BGR-34 produced clinically relevant and statistically significant reductions in all three key measures of glucose control studied -FPG, PPBG and HbA1c- when compared with placebo. BGR-34, showed the promising result with respect to glycemic parameters in NIDDM patient with a significant reduction in fasting blood sugar by 34.3%, postprandial blood sugar 35.5% & glycosylated haemoglobin by 20.31% as compared to placebo group showing a reduction by 13.2%, 10.9% & 10.87% respectively. The trial has also been registered to CTRI, India. This study has been registered in the clinical trial registry-India.

1. (2006).Ethical Guidelines for Biomedical Research on Human Participants.New Delhi:Indian Council of Medical Research.
2. Ahmad, F,Khalid, P,Khan, MM,Rastogi, AK,Kidwai, JR(1989).Insulin like activity in (-) epicatechin.Acta Diabetol Lat,26(4),291-300.
3. Ali, Mahdy K,Wonnerth, A,Huber, K,Wojta, J(2012).Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities.Br J Pharmacol,167(6),1177-1194.
4. Chiasson, JL,Josse, RG,Gomis, R,Hanefeld, M,Karasik, A,Laakso, M(2003).Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.J Am Med Assoc.,290,486-494.
5. Docie, JV(1958).Practical Haemotology.London:J&A Churchill Ltd..
6. Fossati, P,Prencipe, L(1982).Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide.Clin Chem,28(10),2077-2080.
7. Henry, RJ(1974).Clinical Chemistry Principles and Techniques.Newyork:Harper and Row Publication.
8. Hilaly, El,Israili, J,Lyoussi, ZH(2004).Acute and chronic toxicological studies of Ajuga iva in experimental rats.J Ethnopharmacol,91,43-50.
9. Hugget, ASG,Nixon, DA(1957).Use of glucose oxidase, peroxidase, and o-dianisidine in determination of blood and urinary glucose.Lancet,270(6991),368-370.
10. Lillie, RD(1965).Histopathological Techniques and Practical Histochemistry.New York:McGraw Hill Book Co..
11. Lowry, OH,Rosebrough, NJ,Farr, AL,Randall, RJ(1951).Protein measurement with the folin phenol reagent.J Biol Chem,193,265.
12. Mallay HT, Evelyn KA. The determination of bilirubin with the photometric colorimeter. J Biol Chem. 1937;119:481-490.
13. Michael, B,Christian, M,Stephan, K,Susan, S,Jick, C,Meier, R(2008).Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia a nested case-control analysis.Diabetes Care,31(11),2086-2091.
14. Natelson, S.(1957).Micro Techniques of Clinical Chemistry for the Routine Laboratory.Springfield, Dilliners:Thomas.
15. OECD(2008).OECD. Test Guideline 407. Repeated Dose 28-day Oral Toxicity Study in Rodents. 2008..
16. OECD(2001).OECD. Test Guideline 425. Acute Oral Toxicity - Up-and-down Procedure. 2001..
17. OECD(2001).Guidance Document on Acute Oral Toxicity Testing.
18. Patel, DK,Prasad, SK,Kumar, R,Hemalatha, S(2012).An overview on antidiabetic medicinal plants having insulin mimetic property.Asian Pac J Trop Biomed,2(4),320-330.
19. Reitman, S,Frankel, S(1957).A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases.Am J Clin Pathol,28,53.
20. Ridker, PM,Danielson, E,Fonseca, FA(2009).Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the jupiter trial.Lancet,373,1175-1182.
21. Rituparna, C,Bhavtaran, S,Narendra, P(2011).Dipeptidyl peptidase- IV inhibitory activity of Berberis aristata.J Nat Prod,4,158-163.
22. Ritz, ERI,Locatelli, F,Halimi, S(1999).End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions.Am J Kidney Dis,34,795-808.
23. Sandhya, R,Pallavi, M,Suresh, K,Suresh, J,Shankar, P,Aniket, K.(2013).Antiglycation, antioxidant and antidiabetic activity of traditional medicinal plant: rubia cordifolia linn. For management of hyperglycemia.Int J Plant Animal Environ Sci.,213(3-4),42-49.
24. Sangeetha, Marimuthu K,Balaji, HR,Gayathri, RV,Vasanthi, HR(2011).Tinospora cordifolia attenuates oxidative stress and distorted carbohydrate metabolism in experimentally induced type 2 diabetes in rats.J Nat Med.,65,544.
25. Schilter, B,Andersson, C,Anton, R(2003).Guidance on Safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements.Food Chem Toxicol,41,1625-1649.
26. UK prospective diabetes study (UKPDS) group(1998).effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet,352,854-865.
27. Vijayanand, R,Aralelimath, S,Bhisea, B(2012).Anti-diabetic effects of gymnema sylvester extract on streptozotocin induced diabetic rats and possible β-cell protective and regenerative evaluations.Digest J Nanomater Biostruct,7(1),135-142.
28. World health organization(2015).Global Report on Diabetes. 2016.International Diabetes Federation.
29. Wybenga, DR,Pileggi, VJ,Dirstine, PH,Giorgio, JD(1970).Direct manual determination of serum total cholesterol with a single stable reagent.Clin Chem,16(12),980.
30. Zlatkis, A,Zak, B,Boyle, AJ(1953).A new method for the direct determination of serum cholesterol.J Lab Clin Med,41(3),486-492.